Figure 2.

Relative prevalence of genomic biomarkers relevant to therapy in patients with “nonsquamous” stage IV non-small-cell lung cancer (Lung Cancer Center, West German Cancer Center [Department of Medicine, University of Essen], 2021).

ALK, anaplastic lymphoma kinase; BRAF, B-rat fibrosarcoma; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; KRAS, Kirsten rat sarcoma viral oncogene; MET, MET proto-oncogene/receptor tyrosine kinase; NRTK, neurotrophic tyrosine kinase; RET, RET proto-oncogene; ROS1, ROS proto-oncogene 1